IN8bio Presents Durable Survival Improvements in Newly Diagnosed Glioblastoma with Repeat-Doses of DeltEx Drug-Resistant Immunotherapy

IN8bio reported updated Phase I/II data for its DeltEx Drug-Resistant Immunotherapy gamma-delta (γδ) T cells in newly diagnosed glioblastoma. The therapy nearly doubled median progression-free survival to 13.0 months compared to 6.6 months for standard-of-care. Median overall survival climbed to 17.2+ months, with several patients remaining progression-free for multiple years. The treatment was well tolerated with no severe adverse events or dose-limiting toxicities observed.